Drugs / SER-252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07422675 | Feb 2026 → Jan 2027 expected | Parkinson disease | Serina Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07422675 ↗ |
| Known as | PEOZ-apomorphine | “SER-252 (PEOZ-apomorphine) Single subcutaneous dose delivered by enFuse® on body device” NCT07422675 ↗ |
| Route | Subcutaneous | “Some participants will receive a subcutaneous injection of SER-252” NCT07422675 ↗ |